Compare iShares Gold Trust (IAU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs BIO-TECHNE Corp — how do they compare? iShares Gold Trust trades at $78.82 (market cap $61.03B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: iShares Gold Trust is far larger — about 5.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while iShares Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and BIO-TECHNE Corp for 63 Days on average.
| IAU | TECH | |
|---|---|---|
Market Cap | $61.03B | $11.37B |
Volume | 3,374,602 | 3,153,511 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $72.61 |
52-Week Low | $74.21 | $43.31 |
Typical Hold Time | 49 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU shares declined 1.67% to $77.06 amid bearish technical signals, with moving averages and oscillators indicating selling pressure. The stock faces headwinds from rising Treasury yields and Federal Reserve rate uncertainty, though some analysts see potential for recovery if inflation data continues to soften. Recent news highlights gold's sensitivity to economic indicators and monetary policy expectations.
The outlook remains cautious with technical indicators favoring bearish momentum, but potential exists for rebound if rate-hike expectations diminish. Key risks include persistent high yields and dollar strength, while opportunities may emerge from safe-haven demand during market volatility.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
